• Users Online: 228
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 42  |  Issue : 3  |  Page : 88-94

CD135 expression in childhood acute lymphoblastic leukemia: association with chromosomal aberrations and survival


Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Deena M.M Habashy
Clinical Pathology Department, Hematology Unit, Faculty of Medicine, Ain Shams University, Cairo - 11759
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ejh.ejh_30_17

Rights and Permissions

Background Building strategies for targeted therapy in acute lymphoblastic leukemia (ALL) patients has been a challenge over the past few years; this raised the importance of revealing new prognostic markers of which CD135, an fms-like tyrosine kinase 3 (FLT3), expression may play a role in patients’ survival and prognosis. Objective This study aimed at detecting the expression of CD135 in childhood ALL, searching for a possible association with chromosomal aberrations and overall survival (OS). Patients and methods Forty newly diagnosed pediatric ALL patients and 20 age-matched and sex-matched controls were studied for the expression of CD135 by flow cytometry. Results Medians of total leukocytic count and CD135 expression [percentage and mean fluorescence intensity (MFI)] were higher in the patient group compared with controls, whereas medians of hemoglobin and platelet count were higher in controls compared with the patient group (P<0.001). Median of CD135 MFI was higher in the patient group with unfavorable chromosomal aberrations, CD33+ and those with poor outcome than those with favorable chromosomal aberrations, CD33 and those with good outcome (P<0.001). CD135 MFI was inversely correlated to OS in the patient group (P<0.001). Patients with MFI values more than or equal to 2.25 had median survival of 13 months, whereas patients with values less than 2.25 had a median survival of 30 months (P<0.001). Conclusion CD135 is expressed in ALL pediatric patients. High CD135 MFI is associated with unfavorable chromosomal aberrations, poor outcome, and is correlated with shorter OS in those patients, which highlights its possible role in follow-up of ALL patients and disease outcome.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed220    
    Printed8    
    Emailed0    
    PDF Downloaded71    
    Comments [Add]    

Recommend this journal